Go Pro
→ Someone just dumped the biggest gold fund. (From Behind the Markets) (Ad)tc pixel Free PBMWW Stock Alerts

Psyence Biomedical (PBMWW) Financials

$0.03 0.00 (0.00%)
As of 08/21/2026 03:22 PM Eastern
Compare
Annual Income Statements for Psyence Biomedical

Annual Income Statements for Psyence Biomedical

This table shows Psyence Biomedical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025 2026
Period end date 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.30 -51 1.01 -6.94
Consolidated Net Income / (Loss)		 -3.21 -51 1.01 -6.94
Net Income / (Loss) Continuing Operations		 -3.23 -51 1.01 -6.89
Total Pre-Tax Income 		-3.23 -51 1.01 -6.89
Total Operating Income		 -3.23 -2.75 -3.66 -6.23
Total Gross Profit		 0.00 -0.08 -0.48 -0.22
Total Revenue		 0.00 -0.08 -0.48 -0.22
Operating Revenue		 - -0.08 -0.48 -0.22
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.23 2.67 3.18 6.02
Selling, General & Admin Expense		 0.37 0.56 1.21 0.89
Research & Development Expense		 1.61 0.95 0.34 1.47
Depreciation Expense		 0.00 0.00 0.00 0.01
Other Operating Expenses / (Income)		 1.25 1.16 1.62 3.65
Total Other Income / (Expense), net		 0.03 -48 4.66 -0.65
Interest Expense		 0.00 0.05 0.01 0.01
Interest & Investment Income		 0.00 0.00 0.12 0.69
Other Income / (Expense), net		 0.03 -48 4.56 -1.33
Basic Earnings per Share		 ($394.06) ($29,214.06) $32.76 ($12.56)
Weighted Average Basic Shares Outstanding		 8.37K 1.74K 30.89K 2.29M
Diluted Earnings per Share		 ($394.06) ($29,214.06) $32.76 ($12.56)
Weighted Average Diluted Shares Outstanding		 8.37K 1.74K 30.89K 552.28K
Weighted Average Basic & Diluted Shares Outstanding		 5M 1.74K 30.89K 552.28K

Quarterly Income Statements for Psyence Biomedical

No quarterly income statements for Psyence Biomedical are available.

Annual Cash Flow Statements for Psyence Biomedical

This table details how cash moves in and out of Psyence Biomedical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025 2026
Period end date 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -3.06 -51 1.08 -7.78
Net Cash From Operating Activities		 -3.06 -51 1.09 -7.78
Net Cash From Continuing Operating Activities		 -3.06 -51 1.09 -7.78
Net Income / (Loss) Continuing Operations		 -3.21 -51 1.01 -6.94
Consolidated Net Income / (Loss)		 -3.21 -51 1.01 -6.94
Depreciation Expense		 0.00 0.00 0.00 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.15 0.07 0.07 -0.85
Net Cash From Investing Activities		 0.00 -0.01 -0.01 -0.00
Net Cash From Continuing Investing Activities		 0.00 -0.01 -0.01 -0.00
Purchase of Property, Plant & Equipment		 0.00 -0.01 -0.01 -0.00
Net Cash From Financing Activities		 0.00 0.00 0.00 0.00
Net Cash From Continuing Financing Activities		 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Psyence Biomedical

No quarterly cash flow statements for Psyence Biomedical are available.

Annual Balance Sheets for Psyence Biomedical

This table presents Psyence Biomedical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025 2026
Period end date 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 1.83 1.59 1.13 7.32 18
Total Current Assets		 1.75 1.59 1.13 6.56 9.11
Cash & Equivalents		 1.75 1.33 0.73 6.14 7.44
Restricted Cash		 - 0.03 0.03 0.04 0.05
Accounts Receivable		 - 0.15 0.04 0.14 0.11
Prepaid Expenses		 - 0.08 0.32 0.25 1.26
Plant, Property, & Equipment, net		 0.00 0.00 0.01 0.01 0.01
Plant, Property & Equipment, gross		 0.00 0.00 0.01 0.01 0.01
Total Noncurrent Assets		 0.01 0.00 0.00 0.00 8.06
Long-Term Investments		 - - 0.00 0.00 8.06
Total Liabilities & Shareholders' Equity		 1.83 1.59 -9.84 7.32 18
Total Liabilities		 0.13 1.79 12 0.59 0.62
Total Current Liabilities		 0.13 1.79 12 0.59 0.62
Accounts Payable		 0.13 1.79 0.76 0.39 0.41
Other Current Liabilities		 - - 11 0.20 0.22
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.70 -0.20 -22 6.72 17
Total Preferred & Common Equity		 1.70 -0.20 -22 6.72 17
Total Common Equity		 1.70 -0.20 -22 6.72 17
Common Stock		 - 5.93 46 62 79
Retained Earnings		 0.00 -6.30 -57 -56 -63
Other Equity Adjustments		 1.70 0.17 -11 1.42 1.58

Quarterly Balance Sheets for Psyence Biomedical

No quarterly balance sheets for Psyence Biomedical are available.

Annual Metrics And Ratios for Psyence Biomedical

This table displays calculated financial ratios and metrics derived from Psyence Biomedical's official financial filings.

Metric 2023 2024 2025 2026
Period end date 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 13,390,659.00 568,021.00 2,293,277.00
DEI Adjusted Shares Outstanding		 0.00 573.00 568,021.00 2,293,277.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -89,282.81 1.78 -3.02
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% -499.89% 54.81%
EBITDA Growth		 0.00% -1,493.04% 101.76% -939.28%
EBIT Growth		 0.00% -1,493.05% 101.75% -943.86%
NOPAT Growth		 0.00% 14.94% -89.96% -19.24%
Net Income Growth		 0.00% -1,495.53% 101.98% -785.56%
EPS Growth		 0.00% -1,495.53% 101.98% -138.34%
Operating Cash Flow Growth		 0.00% -1,571.24% 102.13% -816.12%
Free Cash Flow Firm Growth		 0.00% 0.00% -284.35% 65.10%
Invested Capital Growth		 0.00% -650.21% 98.35% 485.58%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.12% 100.01% 100.56% 100.73%
Interest Burden Percent		 100.84% 100.10% 112.21% 91.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -428.02% 462.03% -13.29% -58.62%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -708.77%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -428.02% 462.03% -13.29% -58.62%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.26 -1.93 -3.66 -4.36
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -69.07% 1,113.12% -283.61% -22.27%
Return On Investment Capital (ROIC_SIMPLE)		 1,129.69% 8.78% -54.43% -25.75%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.21 -51 0.90 -7.57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.21 -51 0.90 -7.56
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.02 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.02 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.11 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 944.49% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 6.80 -0.40 -0.22 -0.98
Leverage Ratio		 2.28 -0.12 -0.56 1.05
Compound Leverage Factor		 2.30 -0.12 -0.62 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 -9.38 -5.87
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.89 0.09 11.04 14.62
Quick Ratio		 0.83 0.06 10.55 12.12
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 8.24 -15 -5.31
Operating Cash Flow to CapEx		 0.00% -892,020.27% 10,999.17% -3,397,325.33%
Free Cash Flow to Firm to Interest Expense		 0.00 155.74 -1,639.69 -557.15
Operating Cash Flow to Interest Expense		 0.00 -964.96 117.19 -817.04
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -965.07 116.13 -817.07
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 -1.56 -12 -0.19 0.75
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -10 12 0.94
Enterprise Value (EV)		 0.00 0.00 -6.06 -16
Market Capitalization		 0.00 0.00 0.11 0.04
Book Value per Share		 ($23.96) ($12,583.19) $0.50 $7.39
Tangible Book Value per Share		 ($23.96) ($12,583.19) $0.50 $7.39
Total Capital		 -0.20 -22 6.72 17
Total Debt		 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -1.36 -0.76 -6.17 -16
Capital Expenditures (CapEx)		 0.00 0.01 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.56 -12 -0.21 1.00
Debt-free Net Working Capital (DFNWC)		 -0.20 -11 5.97 8.49
Net Working Capital (NWC)		 -0.20 -11 5.97 8.49
Net Nonoperating Expense (NNE)		 0.94 49 -4.67 2.57
Net Nonoperating Obligations (NNO)		 -1.36 10 -6.92 -16
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($182,593.95) $204.69 ($12.56)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 573.00 14.54K 2.29M
Adjusted Diluted Earnings per Share		 $0.00 ($182,593.95) $204.69 ($12.56)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 279.00 4.94K 552.28K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 279.00 4.94K 552.28K
Normalized Net Operating Profit after Tax (NOPAT)		 -2.26 -1.93 -2.56 -4.36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 -965.31 96.73 -794.69
NOPAT to Interest Expense		 0.00 -36.38 -394.69 -458.16
EBIT Less CapEx to Interest Expense		 0.00 -965.41 95.67 -794.71
NOPAT Less CapEx to Interest Expense		 0.00 -36.49 -395.75 -458.18
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Psyence Biomedical

No quarterly metrics and ratios for Psyence Biomedical are available.


Financials Breakdown Chart

Psyence Biomedical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Psyence Biomedical's fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

Psyence Biomedical's net income appears to be on a downward trend, with a most recent value of -$6.94 million in 2026, rising from -$3.21 million in 2023. The previous period was $1.01 million in 2025.

Psyence Biomedical's total operating income in 2026 was -$6.23 million, based on the following breakdown:
  • Total Gross Profit: -$218.49 thousand
  • Total Operating Expenses: $6.02 million

Over the last 3 years, Psyence Biomedical's total revenue changed from $0.00 in 2023 to -$218.49 thousand in 2026, a change of -21,848,500.0%.

Psyence Biomedical's total liabilities were at $623.19 thousand at the end of 2026, a 4.8% increase from 2025, and a 373.4% increase since 2022.

In the past 4 years, Psyence Biomedical's cash and equivalents has ranged from $733.19 thousand in 2024 to $7.44 million in 2026, and is currently $7.44 million as of their latest financial filing in 2026.

Over the last 3 years, Psyence Biomedical's book value per share changed from -23.96 in 2023 to 7.39 in 2026, a change of -130.8%.


Related Companies

Financial statements for NASDAQ:PBMWW last updated on 8/18/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel